Dr Angell joined Glaxo in 1992 after completing a Ph.D in Synthetic Organic Chemistry at the University of Reading. He worked on projects directed towards novel treatments for viral infections (CMV) and asthma. He was a member of the EGFr/erbB2 project team that discovered lapatinib (Tykerb) for breast cancer and the p38 rheumatoid arthritis team that discovered losmapimod. In 2001 he joined Arrow Therapeutics Ltd where he was Head of Discovery, leading a multi-disciplinary team focusing on the early stage antiviral drug discovery projects. The team delivered three preclinical drug candidates starting from Hits-to-Leads screening efforts. He has experience of leading projects in anticancer, antibacterial, antiviral and anti-inflammatory disease areas. He joined the Translational Research Office in November 2012 where his role iinvolves helping PIs at UCL build data packages suitable for translational funding application, particularly focusing on small molecule drug discovery. His research interests include- Small molecule drug discovery from target validation through to candidate selection Medicinal chemistry, compound design and molecular property profiling Design and synthesis of small molecule libraries for screening Hit identification strategies, hit validation and expansion strategies Hits-to-Leads process-finding starting points for new small molecule drug discovery projects